Drug intelligence / Profile preview

URST1 inhibitor

Development stage: Preclinical
Lead developer: Kanagawa Prefectural Cancer Center
Modality: Small Molecules

Overview

URST1 inhibitor is a small molecule inhibitor targeting up-regulated in solid tumor 1 (URST1), a cytokinesis-related protein that is highly expressed in various solid tumors, including breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and oral cancer. URST1 expression is associated with poor clinical outcomes and tumor progression. Inhibition of URST1 by this selective small molecule inhibitor or knockdown via siRNA leads to cell cycle arrest at the G2/M phase, mitotic cell death, and significant suppression of cancer cell growth and invasion. The therapeutic potential of URST1 inhibitors is being investigated for precision medicine in solid tumors.

Other names: selective URST1 inhibitorsmall molecule URST1 inhibitor

Targets

URST1 (Up-regulated in solid tumor 1)

Beyond the preview

Go deeper on URST1 inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on URST1 inhibitor.

Explore the full profile